Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
ALK-positive anaplastic large cell lymphoma (ALK+ ALCL) is a type of ALCL, a rare and aggressive peripheral T-cell non-Hodgkin lymphoma affecting lymph nodes and extranodal sites, which is characterized by the expression of a protein called anaplastic lymphoma kinase (ALK).
Biomarker and diagnostic research for ALK-positive anaplastic large cell lymphoma has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for ALK-positive anaplastic large cell lymphoma.
90 publications have been identified in PubMed for ALK-positive anaplastic large cell lymphoma. Research spans Case Report / Case Series (34%), Basic Science / Preclinical (19%), and Review / Meta-Analysis (16%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 31 | 34% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 6:51 AM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about ALK-positive anaplastic large cell lymphoma
Laboratory research
17 |
19% |
Research summaries | 14 | 16% |
Disease patterns and progression | 12 | 13% |
Testing and diagnosis research | 5 | 6% |
Clinical study results | 5 | 6% |
Other research | 3 | 3% |
New treatment approaches | 3 | 3% |
Wei W (2026). [PMID: 41225182](https://pubmed.ncbi.nlm.nih.gov/41225182/). *Leukemia*. [Gene Therapy / Novel Therapeutics]
Tuteja SK (2026). [PMID: 41773598](https://pubmed.ncbi.nlm.nih.gov/41773598/). *Br J Haematol*. [Diagnostic / Biomarker]
Mori T (2026). [PMID: 41457564](https://pubmed.ncbi.nlm.nih.gov/41457564/). *Cancer Sci*. [Clinical Trial Publication]
Kao EY (2026). [PMID: 30085561](https://pubmed.ncbi.nlm.nih.gov/30085561/). *Unknown Journal*. [Other]
DU CK (2026). [PMID: 41846374](https://pubmed.ncbi.nlm.nih.gov/41846374/). *Zhongguo Shi Yan Xue Ye Xue Za Zhi*. [Review / Meta-Analysis]
Feldman AL (2026). [PMID: 41329859](https://pubmed.ncbi.nlm.nih.gov/41329859/). *Blood*. [Basic Science / Preclinical]
Coelho M (2026). [PMID: 41502350](https://pubmed.ncbi.nlm.nih.gov/41502350/). *Pediatr Blood Cancer*. [Other]
Caserta S (2026). [PMID: 41905770](https://pubmed.ncbi.nlm.nih.gov/41905770/). *Br J Haematol*. [Review / Meta-Analysis]
Kaseb H (2026). [PMID: 30725835](https://pubmed.ncbi.nlm.nih.gov/30725835/). *Unknown Journal*. [Review / Meta-Analysis]
Pramanik D (2026). [PMID: 41871898](https://pubmed.ncbi.nlm.nih.gov/41871898/). *BMJ Case Rep*. [Case Report / Case Series]